This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Olivari, M. T. Articles by Guazzi, M. D. Search for Related Content PubMed PubMed Citation Articles by Olivari, M. T. Articles by Guazzi, M. D.

Circulation, Vol 59, 1056-1062, Copyright © 1979 by American Heart Association

ARTICLES

Treatment of hypertension with nifedipine, a calcium antagonistic agent

MT Olivari, C Bartorelli, A Polese, C Fiorentini, P Moruzzi and MD Guazzi

Hemodynamic monitoring after a single dose (10 mg) of nifedipine in 27 primary hypertensive subjects (diastolic pressure greater than 110 mm Hg) documented that this calcium antagonistic agent exerts a potent arteriolar vasodilating action, which results in prompt (-21% of control at 30 minutes) and persistent (-16% of control at 120 minutes) fall in mean arterial pressure associated with a rise in cardiac output and pulse rate. The same patients received oral treatment for 3 weeks. Hourly pressure readings showed that 1) the antihypertensive response to each dose lasts 8--12 hours; and 2) nifedipine every 6 hours significantly reduced blood pressure throughout the 24 hours, without postural hypotension. Side effect were short-lasting (headache in five patients, palpitation without arrhythmias in eight patients, burning sensation in the face and legs in five patients and sporadic extrasystoles in five patients) and tended to disappear with continued treatment. Development of drug resistance, sodium retention, plasma volume expansion, renin release or angina pectoris were not observed during the study. Although these findings seem to differentiate nifedipine from other vasodilators currently used in the treatment of hypertension, broader experience and more prolonged trials with nifedipine as an antihypertensive agent will be needed before conclusions can be drawn on these particular aspects.

This article has been cited by other articles:

				G.Y.H. Lip, C. Lydakis, and D.G. Beevers Management of patients with myocardial infarction and hypertension Eur. Heart J., July 2, 2000; 21(14): 1125 - 1134. [PDF]

				C.-T. Ting, J.-W. Chen, M.-S. Chang, and F. C. P. Yin Arterial Hemodynamics in Human Hypertension : Effects of the Calcium Channel Antagonist Nifedipine Hypertension, June 1, 1995; 25(6): 1326 - 1332. [Abstract] [Full Text]

				B. Komsuoglu, B. Sengun, A. Bayram, and S. S. Komsuoglu Treatment of Hypertensive Urgencies with Oral Nifedipine, Nicardipine, and Captopril Angiology, June 1, 1991; 42(6): 447 - 454. [Abstract] [PDF]

				M. Yurtkuran, K. Dilek, M. Gullulu, M. Yavuz, and A. Muftuoglu Effects of Sublingual Administration of Nifedipine on Arterial Pressure, Plasma Renin Activity, and Glomerular Filtration Rate in Essential Hypertension Angiology, September 1, 1989; 40(9): 791 - 794. [Abstract] [PDF]

				E. Lorentsen and K. Landmark The Acute Effects of Nifedipine on Calf and Forefoot Blood Flow in Patients with Peripheral Arterial Insufficiency Angiology, January 1, 1983; 34(1): 46 - 52. [Abstract] [PDF]

				M. D. Winniford, J. T. Willerson, and L. D. Hillis Calcium Antagonists in the Treatment of Individuals with Ischemic Heart Disease Angiology, August 1, 1982; 33(8): 522 - 539. [Abstract] [PDF]